Clinical Trial Update: Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating short-term sintilimab in combination with a taxane and carboplatin as neoadjuvant therapy for triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Sintilimab (sintilimab)
• Taxane (paclitaxel or docetaxel)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Triple-negative Breast Cancer | Phase 4 | Status: NOT_YET_RECRUITING